{"entity":{"id":"nct06137144","kind":"trial","name":"AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.","aka":["PRIMAVERA"],"tldr":"A phase 1/2 trial of AZD3470, Pembrolizumab in hodgkin lymphoma and non-hodgkin lymphoma, run by AstraZeneca, now recruiting.","summary":"AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. is a phase 1/2 interventional study registered as NCT06137144 by AstraZeneca, with 161 participants planned, started 2024-01-23 and due to reach its primary completion in 2029-05-03. Interventions recorded: AZD3470, Pembrolizumab. Conditions listed: Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06137144","url":"https://clinicaltrials.gov/study/NCT06137144"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["azd3470","pembrolizumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06137144","phase":"1/2","setting":"A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies","sponsor":"AstraZeneca","participation":[{"nct":"NCT06137144","source":"https://clinicaltrials.gov/study/NCT06137144","fetchedAt":"2026-10-07T16:54:16.815Z","studySha256":"e0d0f06366e37574977ef68d485d47ebae99c40239d9d486691eff34ca85b7c6","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-14","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"12 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":161,"enrolmentType":"ESTIMATED","siteCount":39,"recruitingSiteCount":26,"countries":["Australia","Brazil","China","France","Germany","Italy","Japan","South Korea","Spain","United Kingdom","United States"]}],"started":"2024-01-23","startedType":"actual","enrolled":161,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06137144/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"azd3470","kind":"drug","name":"AZD3470","route":"/drugs/azd3470/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}